TruScreen expands African operations across four nations

• Zerocancer Professional Consult and Biotech Medical Supply were appointed as distributors for Nigeria, Ghana, Côte d'Ivoire, and Rwanda.
• Following the announcement, the TruScreen share price was unchanged at $0.012.
• The appointments advance TruScreen's strategy for African expansion to target public screening programmes and meet World Health Organisation screening objectives.

TruScreen Group (ASX:TRU) appointed new distributors across Nigeria, Ghana, Côte d'Ivoire, and Rwanda to support public cancer screening programmes.

The newly established distribution partnerships support the company's broader push into the African market.

Nigerian product regulatory approval is expected to take 3 to 6 months, alongside preparations for a 300-patient clinical evaluation.

Data collected from the evaluation will support the application for the company's inclusion in Nigerian national screening guidelines and government health programmes.

Following the announcement, the TruScreen share price was unchanged at $0.012.

The company specialises in artificial intelligence-enabled medical devices designed for real-time cervical cancer screening.

Its technology targets emerging markets, aiming to close screening gaps in regions lacking conventional laboratory infrastructure.